Skip to main content
Top
Published in: Journal of Neurology 8/2014

Open Access 01-08-2014 | Original Communication

Mortality of patients with multiple sclerosis: a cohort study in UK primary care

Authors: S. S. Jick, L. Li, G. J. Falcone, Z. P. Vassilev, M.-A. Wallander

Published in: Journal of Neurology | Issue 8/2014

Login to get access

Abstract

We aimed to estimate rates, causes and risk factors of all-cause mortality in a large population-based cohort of multiple sclerosis (MS) patients compared with patients without MS. Using data from the UK General Practice Research Database, we identified MS cases diagnosed during 2001–2006 and validated using patients’ original records where possible. We also included MS cases during 1993–2000 identified and validated in an earlier study. Cases were matched to up to ten referents without MS by age, sex, index date (date of first MS diagnosis for cases and equivalent reference date for controls), general practice and length of medical history before first MS diagnosis. Patients were followed up to identify deaths; hazard ratios (HRs) and 95 % confidence intervals (CIs) were estimated using Cox-proportional regression. MS patients (N = 1,822) had a significantly increased risk of all-cause mortality compared with referents (N = 18,211); adjusted HR 1.7 (95 % CI 1.4–2.1). Compared with referents, female MS patients had a higher but not significantly different HR for death than males; adjusted HR 1.86 (95 % CI 1.46–2.38) vs. HR 1.31 (95 % CI 0.93–1.84), respectively. The most commonly recorded cause of death in MS patients was ‘MS’ (41 %), with a higher proportion recorded among younger patients. A significantly higher proportion of referents than MS patients had cancer recorded as cause of death (40 vs. 19 %). Patients with MS have a significant 1.7-fold increased risk of all-cause mortality compared with the general population. MS is the most commonly recorded cause of death among MS patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vecsei L, Milanov I (2006) The epidemiology of multiple sclerosis in Europe. Eur J Neurol 13:700–722CrossRefPubMed Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vecsei L, Milanov I (2006) The epidemiology of multiple sclerosis in Europe. Eur J Neurol 13:700–722CrossRefPubMed
3.
go back to reference Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ (2010) Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 69:4–14PubMedCentralCrossRefPubMed Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ (2010) Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 69:4–14PubMedCentralCrossRefPubMed
4.
go back to reference Williams T, van Staa TP, Puri S, Eaton S (2012) Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource. Ther Adv Drug Saf 3:89–99PubMedCentralCrossRefPubMed Williams T, van Staa TP, Puri S, Eaton S (2012) Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource. Ther Adv Drug Saf 3:89–99PubMedCentralCrossRefPubMed
5.
go back to reference Alonso A, Jick SS, Hernan MA (2006) Allergy, histamine 1 receptor blockers, and the risk of multiple sclerosis. Neurology 66:572–575CrossRefPubMed Alonso A, Jick SS, Hernan MA (2006) Allergy, histamine 1 receptor blockers, and the risk of multiple sclerosis. Neurology 66:572–575CrossRefPubMed
6.
go back to reference Alonso A, Jick SS, Jick H, Hernan MA (2006) Antibiotic use and risk of multiple sclerosis. Am J Epidemiol 163:997–1002CrossRefPubMed Alonso A, Jick SS, Jick H, Hernan MA (2006) Antibiotic use and risk of multiple sclerosis. Am J Epidemiol 163:997–1002CrossRefPubMed
7.
go back to reference Alonso A, Jick SS, Olek MJ, Ascherio A, Jick H, Hernan MA (2005) Recent use of oral contraceptives and the risk of multiple sclerosis. Arch Neurol 62:1362–1365CrossRefPubMed Alonso A, Jick SS, Olek MJ, Ascherio A, Jick H, Hernan MA (2005) Recent use of oral contraceptives and the risk of multiple sclerosis. Arch Neurol 62:1362–1365CrossRefPubMed
8.
go back to reference Alonso A, Jick SS, Olek MJ, Hernan MA (2007) Incidence of multiple sclerosis in the United Kingdom: findings from a population-based cohort. J Neurol 254:1736–1741CrossRefPubMed Alonso A, Jick SS, Olek MJ, Hernan MA (2007) Incidence of multiple sclerosis in the United Kingdom: findings from a population-based cohort. J Neurol 254:1736–1741CrossRefPubMed
9.
go back to reference Bazelier MT, van Staa T, Uitdehaag BM, Cooper C, Leufkens HG, Vestergaard P, Bentzen J, de Vries F (2011) The risk of fracture in patients with multiple sclerosis: the UK general practice research database. J Bone Miner Res 26:2271–2279PubMedCentralCrossRefPubMed Bazelier MT, van Staa T, Uitdehaag BM, Cooper C, Leufkens HG, Vestergaard P, Bentzen J, de Vries F (2011) The risk of fracture in patients with multiple sclerosis: the UK general practice research database. J Bone Miner Res 26:2271–2279PubMedCentralCrossRefPubMed
10.
go back to reference Hernan MA, Jick SS (2006) Hepatitis B vaccination and multiple sclerosis: the jury is still out. Pharmacoepidemiol Drug Saf 15:653–655CrossRefPubMed Hernan MA, Jick SS (2006) Hepatitis B vaccination and multiple sclerosis: the jury is still out. Pharmacoepidemiol Drug Saf 15:653–655CrossRefPubMed
11.
go back to reference Hernan MA, Jick SS, Logroscino G, Olek MJ, Ascherio A, Jick H (2005) Cigarette smoking and the progression of multiple sclerosis. Brain 128:1461–1465CrossRefPubMed Hernan MA, Jick SS, Logroscino G, Olek MJ, Ascherio A, Jick H (2005) Cigarette smoking and the progression of multiple sclerosis. Brain 128:1461–1465CrossRefPubMed
12.
go back to reference Hernan MA, Jick SS, Olek MJ, Jick H (2004) Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology 63:838–842CrossRefPubMed Hernan MA, Jick SS, Olek MJ, Jick H (2004) Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology 63:838–842CrossRefPubMed
13.
go back to reference Mackenzie IS, Morant SV, Bloomfield GA, MacDonald TM, O’Riordan J (2014) Incidence and prevalence of multiple sclerosis in the UK 1990–2010: a descriptive study in the General Practice Research Database. J Neurol Neurosurg Psychiatry 85:76–84PubMedCentralCrossRefPubMed Mackenzie IS, Morant SV, Bloomfield GA, MacDonald TM, O’Riordan J (2014) Incidence and prevalence of multiple sclerosis in the UK 1990–2010: a descriptive study in the General Practice Research Database. J Neurol Neurosurg Psychiatry 85:76–84PubMedCentralCrossRefPubMed
14.
go back to reference Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O’Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58:840–846CrossRefPubMed Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O’Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58:840–846CrossRefPubMed
15.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRefPubMed
16.
go back to reference Kingwell E, van der Kop M, Zhao Y, Shirani A, Zhu F, Oger J, Tremlett H (2012) Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada. J Neurol Neurosurg Psychiatry 83:61–66CrossRefPubMed Kingwell E, van der Kop M, Zhao Y, Shirani A, Zhu F, Oger J, Tremlett H (2012) Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada. J Neurol Neurosurg Psychiatry 83:61–66CrossRefPubMed
17.
go back to reference Lalmohamed A, Bazelier MT, Van Staa TP, Uitdehaag BM, Leufkens HG, De Boer A, De Vries F (2012) Causes of death in patients with multiple sclerosis and matched referent subjects: a population-based cohort study. Eur J Neurol 19:1007–1014CrossRefPubMed Lalmohamed A, Bazelier MT, Van Staa TP, Uitdehaag BM, Leufkens HG, De Boer A, De Vries F (2012) Causes of death in patients with multiple sclerosis and matched referent subjects: a population-based cohort study. Eur J Neurol 19:1007–1014CrossRefPubMed
18.
go back to reference Leray E, Morrissey S, Yaouanq J, Coustans M, Le Page E, Chaperon J, Edan G (2007) Long-term survival of patients with multiple sclerosis in West France. Mult Scler 13:865–874CrossRefPubMed Leray E, Morrissey S, Yaouanq J, Coustans M, Le Page E, Chaperon J, Edan G (2007) Long-term survival of patients with multiple sclerosis in West France. Mult Scler 13:865–874CrossRefPubMed
19.
go back to reference Sumelahti ML, Hakama M, Elovaara I, Pukkala E (2010) Causes of death among patients with multiple sclerosis. Mult Scler 16:1437–1442CrossRefPubMed Sumelahti ML, Hakama M, Elovaara I, Pukkala E (2010) Causes of death among patients with multiple sclerosis. Mult Scler 16:1437–1442CrossRefPubMed
20.
go back to reference Bronnum-Hansen H, Koch-Henriksen N, Stenager E (2004) Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 127:844–850CrossRefPubMed Bronnum-Hansen H, Koch-Henriksen N, Stenager E (2004) Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 127:844–850CrossRefPubMed
21.
go back to reference Grytten Torkildsen N, Lie SA, Aarseth JH, Nyland H, Myhr KM (2008) Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway. Mult Scler 14:1191–1198CrossRefPubMed Grytten Torkildsen N, Lie SA, Aarseth JH, Nyland H, Myhr KM (2008) Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway. Mult Scler 14:1191–1198CrossRefPubMed
22.
go back to reference Ragonese P, Aridon P, Salemi G, D’Amelio M, Savettieri G (2008) Mortality in multiple sclerosis: a review. Eur J Neurol 15:123–127CrossRefPubMed Ragonese P, Aridon P, Salemi G, D’Amelio M, Savettieri G (2008) Mortality in multiple sclerosis: a review. Eur J Neurol 15:123–127CrossRefPubMed
23.
go back to reference Pompili M, Forte A, Palermo M, Stefani H, Lamis DA, Serafini G, Amore M, Girardi P (2012) Suicide risk in multiple sclerosis: a systematic review of current literature. J Psychosom Res 73:411–417CrossRefPubMed Pompili M, Forte A, Palermo M, Stefani H, Lamis DA, Serafini G, Amore M, Girardi P (2012) Suicide risk in multiple sclerosis: a systematic review of current literature. J Psychosom Res 73:411–417CrossRefPubMed
24.
go back to reference Paty DW, Li DK (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 43:662–667CrossRefPubMed Paty DW, Li DK (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 43:662–667CrossRefPubMed
25.
go back to reference The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 43:655–661CrossRef The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 43:655–661CrossRef
26.
go back to reference Trojano M, Pellegrini F, Fuiani A, Paolicelli D, Zipoli V, Zimatore GB, Di Monte E, Portaccio E, Lepore V, Livrea P, Amato MP (2007) New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 61:300–306CrossRefPubMed Trojano M, Pellegrini F, Fuiani A, Paolicelli D, Zipoli V, Zimatore GB, Di Monte E, Portaccio E, Lepore V, Livrea P, Amato MP (2007) New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 61:300–306CrossRefPubMed
27.
go back to reference Goodin DS, Ebers GC, Cutter G, Cook SD, O’Donnell T, Reder AT, Kremenchutzky M, Oger J, Rametta M, Beckmann K, Knappertz V (2012) Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNbeta-1b study. BMJ Open 2(6). doi:10.1136/bmjopen-2012-001972 Goodin DS, Ebers GC, Cutter G, Cook SD, O’Donnell T, Reder AT, Kremenchutzky M, Oger J, Rametta M, Beckmann K, Knappertz V (2012) Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNbeta-1b study. BMJ Open 2(6). doi:10.​1136/​bmjopen-2012-001972
28.
go back to reference Goodin DS, Reder AT, Ebers GC, Cutter G, Kremenchutzky M, Oger J, Langdon D, Rametta M, Beckmann K, DeSimone TM, Knappertz V (2012) Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNbeta-1b trial. Neurology 78:1315–1322PubMedCentralCrossRefPubMed Goodin DS, Reder AT, Ebers GC, Cutter G, Kremenchutzky M, Oger J, Langdon D, Rametta M, Beckmann K, DeSimone TM, Knappertz V (2012) Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNbeta-1b trial. Neurology 78:1315–1322PubMedCentralCrossRefPubMed
Metadata
Title
Mortality of patients with multiple sclerosis: a cohort study in UK primary care
Authors
S. S. Jick
L. Li
G. J. Falcone
Z. P. Vassilev
M.-A. Wallander
Publication date
01-08-2014
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 8/2014
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-014-7370-3

Other articles of this Issue 8/2014

Journal of Neurology 8/2014 Go to the issue

Pioneers in Neurology

Theodor Meynert (1833–1892)